Sinopharm Group Co. Ltd.
SHTDY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $286,042,998 | $289,781,120 | $294,726,810 | $295,619,285 |
| % Growth | -1.3% | -1.7% | -0.3% | – |
| Cost of Goods Sold | $265,267,567 | $267,469,025 | $272,783,515 | $270,378,288 |
| Gross Profit | $20,775,431 | $22,312,095 | $21,943,295 | $25,240,997 |
| % Margin | 7.3% | 7.7% | 7.4% | 8.5% |
| R&D Expenses | $123,355 | $0 | $0 | $0 |
| G&A Expenses | $3,273,775 | $4,498,388 | $3,915,156 | $4,710,320 |
| SG&A Expenses | $12,505,496 | $13,188,921 | $12,383,262 | $13,085,514 |
| Sales & Mktg Exp. | $7,844,858 | $8,679,422 | $8,479,217 | $9,037,884 |
| Other Operating Expenses | $1,005,005 | $1,156,401 | $1,338,403 | $2,117,008 |
| Operating Expenses | $13,633,855 | $14,345,322 | $13,721,665 | $15,202,522 |
| Operating Income | $7,141,575 | $7,966,773 | $8,221,630 | $10,375,992 |
| % Margin | 2.5% | 2.7% | 2.8% | 3.5% |
| Other Income/Exp. Net | $56,511 | -$1,562,363 | -$625,141 | $270,114 |
| Pre-Tax Income | $7,198,087 | $6,404,410 | $7,596,489 | $10,646,106 |
| Tax Expense | $1,869,748 | $1,880,032 | $1,697,273 | $2,529,509 |
| Net Income | $3,457,714 | $3,345,808 | $3,703,875 | $4,949,321 |
| % Margin | 1.2% | 1.2% | 1.3% | 1.7% |
| EPS | 5.55 | 5.35 | 5.95 | 7.95 |
| % Growth | 3.7% | -10.1% | -25.2% | – |
| EPS Diluted | 5.55 | 5.35 | 5.95 | 7.95 |
| Weighted Avg Shares Out | 623,012 | 622,621 | 624,106 | 623,364 |
| Weighted Avg Shares Out Dil | 623,012 | 622,621 | 624,106 | 623,364 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$778,476 |
| Interest Expense | $457,107 | $1,137,486 | $965,502 | $0 |
| Depreciation & Amortization | $2,233,388 | $1,206,354 | $1,149,524 | $1,010,805 |
| EBITDA | $9,934,208 | $10,647,547 | $9,527,394 | $13,496,089 |
| % Margin | 3.5% | 3.7% | 3.2% | 4.6% |